Salute e Benessere

EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction…

EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level. EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level. Vincent Brichard, Venture Partner at EQT Life Sciences and board member at ImCheck Therapeutics, said : "We are immensely proud to have supported ImCheck's…
PR Newswire
22/10/2025

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES

On September 15, 2025, the Company issued Debentures for an aggregate principal amount of $335,670 convertible into common shares in the capital of the Company ("Shares") at any time, at the option of the holders thereof, at the closing price of the Shares on the Canadian Securities Exchange (the "CSE") on the day notice of conversion is received by the Company, subject to the pricing requirements in the policies of the CSE. The Debentures bear interest at a rate of 10% per…
PR Newswire
22/10/2025

Onco3R Therapeutics reports first pre-clinical data from its best-in-class…

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2 programs identified: IND enabling studies anticipated in mid-2026 Leuven, Belgium, October 22, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced that it will present...
Nasdaq GlobeNewswire
22/10/2025

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Dr. Eric Fain commented: "Developing technology to treat heart failure is a true passion of mine and so I am honored to join Berlin Heals at such a pivotal moment in the company's development and strategic planning. C-MIC technology has the potential to be a true breakthrough in the treatment of these difficult to manage patients and to greatly improve patient outcomes and quality of life across the broad spectrum of chronic heart failure." Dr.Eric Faincommented: "Developing…
PR Newswire
22/10/2025

Nomination Committee appointed for SciBase Holding's Annual General Meeting in…

Derek Maetzold (Castle Biosciences Inc) Derek Maetzold(Castle Biosciences Inc) Maria Anderkvist (Coeli Wealth Management), Jesper Høiland (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding onJune 17, 2025.The Annual General Meeting of SciBase Holding AB (publ) will be held onMay 19, 2026...
PR Newswire
22/10/2025

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from…

Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG - at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. Early clinical data indicate that these…
PR Newswire
22/10/2025

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial…

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; safety profile consistent with known profile of Cosentyx 1 Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥50 2, with limited options available Basel, October 22, 2025 – Novartis today...
Nasdaq GlobeNewswire
22/10/2025

Ipsen delivers strong sales in the first nine months of 2025 and further…

Year-to-date total sales growth of 12.1% at CER 1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0% 2at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior...
Nasdaq GlobeNewswire
22/10/2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline…

Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable...
Nasdaq GlobeNewswire
22/10/2025

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology…

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing...
Nasdaq GlobeNewswire
22/10/2025

Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary…

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 studyEfdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a...
Nasdaq GlobeNewswire
22/10/2025

Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends…

Emphysema Market Summary Emphysema Market Summary Discover the emphysema new treatment @New Treatments for Emphysema Key Factors Driving the Growth of the Emphysema Market Rising Prevalence of Emphysema and COPD The increasing prevalence of COPD, including emphysema, is a primary driver. Factors such as smoking, air pollution, and genetic predispositions contribute to this rise. In 2024, DelveInsight estimated that the 7MM had around31 milliondiagnosed cases of...
PR Newswire
21/10/2025

Momcozy partners with The Modern Midwife to tackle mums' biggest feeding…

The Q&A is part of a wider Momcozy Brand Day initiative working with the UK's largest online parenting community, Mumsnet. With millions of mums visiting every month, Marie will be answering real mum concerns and challenges with tangible advice and product recommendations that can make the experience easier and more comfortable for both parent and baby. The Q&A is part of a wider Momcozy Brand Day initiative working with the UK's largest online parenting community, Mumsnet. With millions…
PR Newswire
21/10/2025

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has acquired an additional $200,000 worth of Ethereum (ETH), bringing the Company’s total investment in ETH to $2 million.This purchase was executed under Cosmos Health’s previously announced $300 million digital assets facility, which underpins the Company’s strategy to broaden and strengthen its portfolio through targeted...
Nasdaq GlobeNewswire
21/10/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from October 13th to October 17th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1113/10/2025FR001025915069...
Nasdaq GlobeNewswire
21/10/2025

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

Curia’s Burlington site has been part of the company’s network since 2010. The facility specializes in drug product manufacturing of vials and prefilled syringes for late-stage clinical trials and commercial products. The site is known for its capabilities to handle solvent-based processes, highly viscous products and controlled substances. It also houses an on-site process development lab supporting mixing studies, scale-up and formulation development.“Curia employees play a crucial role...
Nasdaq GlobeNewswire
21/10/2025

GLP-1 Agonists Market worth $170.75 billion in 2033 with 13.0% CAGR |…

Browse in-depth TOC on "GLP-1 Analogues Market"400 - Tables45 - Figures300- Pages Browse in-depth TOC on "GLP-1 Analogues Market" 400 - Tables 45 - Figures 300- Pages By indication,the GLP-1 Agonists market is segmented into diabetes, obesity and other indications. In 2024, the diabetes segment dominated the market. GLP-1 agonists are becoming a key drug class in diabetes care because of their proven benefits in glycemic control, weight reduction, and cardiovascular risk...
PR Newswire
21/10/2025

JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand…

Backed by rigorous scientific research and clinical trials, Foltène's products are recognized by leading research institutions worldwide. Today, the brand is sold in 30+ countries, trusted and loved by consumers globally. Backed by rigorous scientific research and clinical trials, Foltène's products are recognized by leading research institutions worldwide. Today, the brand is sold in 30+ countries, trusted and loved by consumers globally. This acquisition represents a full global...
PR Newswire
21/10/2025

Novo Holdings to make changes to its Board of Directors

He joined Novo Nordisk in 1992 and has held various financial leadership positions in the company, including regional CFO roles in Japan and North America, before joining Executive Management in 2017. In 2019, Lars Green joined Novozymes (Novonesis) where he served as CFO until the end of 2023. He joined Novo Nordisk in 1992 and has held various financial leadership positions in the company, including regional CFO roles inJapanandNorth America, before joining Executive Management in 2017...
PR Newswire
21/10/2025

The Novo Nordisk Foundation proposes new candidates for election as members of…

Kasim Kutay and the employee-elected board members Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau will remain on the Board. Kasim Kutayand the employee-elected board membersElisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen andThomas Rantzauwill remain on the Board. Furthermore, the Foundation plans to proposeHelena Saxonand one additional member for election to Novo Nordisk's Board at the company's Annual General Meeting on...
PR Newswire
21/10/2025

FREESMO Launches up to 50% Off Plus £20 Amazon Voucher for New Customers

The offers are available for a limited time, starting now and running throughout the coming weeks. No need to wait for Black Friday—customers can shop exclusive deals today at www.freesmo.co.uk. The offers areavailable for a limited time,starting now and running throughout the coming weeks.No need to wait for Black Friday —customers can shop exclusive deals today at www.freesmo.co.uk . FREESMO's campaign encourages smokers to take action now – combining major savings with...
PR Newswire
21/10/2025

Microban International Launches EcoFresh Odor-Capture Technology for Active and…

EcoFresh captures a diverse set of odorants, including sweat/foot/body odor (carboxylic acids), aging body odor (aldehydes), smoke odor (aromatics), fish odor (amines and sulfides) and more. It provides fast-acting odor capture, working in real time to prevent treated materials from becoming saturated or overwhelmed by odorants. This technology outperforms activated carbon fabrics while offering unmatched fabric types and color options, creating lasting performance and extending use of…
PR Newswire
21/10/2025

Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in…

The 2026 Award is focused on research in paediatric oncology, specifically sarcomasPaediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little innovation in treatment progress over the past 40 yearsThe winning project will be awarded a research grant of €250,000Applications are open to young investigators of all nationalities until 31 January 2026 – all information available atprize.recordati.comMilan, 21st October...
Nasdaq GlobeNewswire
21/10/2025

Consortium consisting of Nordic Capital and Permira lowers the minimum…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, October 21, 2025– With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document, as amended by the supplements dated 29 September 2025 and 15 October 2025, respectively (the "Offer Document " ) concerning the all-cash...
Nasdaq GlobeNewswire
21/10/2025
Altri  Comunicati